Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001193125-21-252855
Filing Date
2021-08-20
Accepted
2021-08-20 17:02:41
Documents
92
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A d199993d10qa.htm   iXBRL 10-Q/A 3271453
2 EX-31.1 d199993dex311.htm EX-31.1 10587
3 EX-31.2 d199993dex312.htm EX-31.2 10899
4 EX-32.1 d199993dex321.htm EX-32.1 4736
5 EX-32.2 d199993dex322.htm EX-32.2 4737
11 GRAPHIC g199993g0809233221818.jpg GRAPHIC 61977
  Complete submission text file 0001193125-21-252855.txt   15664431

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA atai-20210630.xsd EX-101.SCH 115088
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atai-20210630_cal.xml EX-101.CAL 54272
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atai-20210630_def.xml EX-101.DEF 569395
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20210630_lab.xml EX-101.LAB 742188
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20210630_pre.xml EX-101.PRE 709574
12 EXTRACTED XBRL INSTANCE DOCUMENT d199993d10qa_htm.xml XML 3336882
Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 (617) 699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40493 | Film No.: 211194502
SIC: 2834 Pharmaceutical Preparations